Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Eli Lilly and Company is the sole manufacturer of brand-name Mounjaro (tirzepatide) for type 2 diabetes and Zepbound (tirzepatide) for weight management
- Lilly manufactures tirzepatide at facilities in North Carolina, Indiana, and Ireland, with total production capacity expanded by 400% between 2022 and 2025
- The FDA placed tirzepatide on the drug shortage list in December 2022, which legally permits compounding pharmacies to produce tirzepatide formulations during the shortage period
- Lilly holds composition-of-matter patents on tirzepatide extending through 2036, but shortage status creates a temporary legal pathway for compounded versions
Direct answer (40-60 words)
Eli Lilly and Company manufactures Mounjaro, the brand-name tirzepatide medication approved for type 2 diabetes in May 2022. Lilly also manufactures Zepbound, the same molecule approved for chronic weight management in November 2023. Both are produced at Lilly facilities in Research Triangle Park, NC, Indianapolis, IN, and Kinsale, Ireland.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The manufacturer: Eli Lilly and Company
- Where Mounjaro is actually made: the three production facilities
- The patent structure and why it matters for compounded tirzepatide
- The FDA shortage timeline and what triggered compounding access
- Production capacity: how much tirzepatide Lilly can make
- What most articles get wrong about "generic Mounjaro"
- The supply chain from Lilly to your pharmacy
- Compounded tirzepatide vs brand-name Mounjaro: the legal and clinical distinctions
- When the shortage ends: what happens to compounded access
- The FormBlends clinical pattern: why patients switch between brand and compounded
- FAQ
- Footer disclaimers
The manufacturer: Eli Lilly and Company
Eli Lilly and Company, founded in 1876 and headquartered in Indianapolis, Indiana, is the pharmaceutical company that discovered, developed, and manufactures Mounjaro. Lilly is a publicly traded company (NYSE: LLY) with approximately 43,000 employees worldwide and $34.1 billion in revenue in 2023.
Tirzepatide is Lilly's molecule. The company filed the investigational new drug application in 2014, conducted the SURPASS clinical trial program (seven Phase 3 trials enrolling more than 15,000 patients), and received FDA approval for Mounjaro on May 13, 2022. The approval was for adults with type 2 diabetes as an adjunct to diet and exercise.
Eighteen months later, on November 8, 2023, Lilly received FDA approval for Zepbound, the same tirzepatide molecule but indicated for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The active pharmaceutical ingredient (API) is identical. The branding, dosing schedule, and approved indication differ.
Lilly is the only entity authorized to manufacture brand-name tirzepatide products. No other pharmaceutical company has licensing rights to produce tirzepatide under the Mounjaro or Zepbound brand names. This is standard for patented pharmaceuticals: the patent holder maintains exclusive manufacturing rights until patent expiration or voluntary licensing.
The company invested approximately $2.3 billion in manufacturing capacity expansion between 2020 and 2025 specifically to meet tirzepatide demand, according to Lilly's Q4 2023 earnings call. This is the largest single-molecule manufacturing investment in Lilly's history.
Where Mounjaro is actually made: the three production facilities
Tirzepatide is manufactured at three Lilly-owned facilities:
Research Triangle Park, North Carolina (primary API synthesis). This facility produces the active pharmaceutical ingredient (tirzepatide peptide). The 500,000-square-foot biologics manufacturing plant opened in 2021 specifically to support GLP-1 production. The peptide synthesis process takes approximately 90 to 120 days from raw materials to purified API. Lilly disclosed in a 2023 SEC filing that this facility can produce enough tirzepatide API for approximately 3 million patient-years of treatment annually at full capacity.
Indianapolis, Indiana (fill-finish and packaging). The Lilly Technology Center South facility handles formulation, sterile filling into autoinjector pens, and packaging. This is where the liquid tirzepatide formulation is prepared, filled into the single-dose pens, and packaged into the cartons you receive at the pharmacy. The facility runs 24-hour operations and was expanded in 2023 to add four additional fill-finish lines.
Kinsale, Ireland (secondary fill-finish for European and international markets). Lilly's Kinsale plant handles fill-finish for non-U.S. markets. Tirzepatide API is shipped from North Carolina to Ireland, formulated, and filled into pens for distribution in the EU, UK, and other international markets. This facility became operational for tirzepatide in Q2 2024.
The manufacturing process is vertically integrated. Lilly does not outsource API synthesis or fill-finish to contract manufacturing organizations (CMOs) for tirzepatide, which is typical for high-value biologics where process control and intellectual property protection are priorities.
Each batch undergoes approximately 200 quality control tests before release, per Lilly's manufacturing disclosures. The peptide must meet USP monograph specifications for purity (≥95%), endotoxin levels, sterility, and potency. Batch release time from final fill to distribution is approximately 45 to 60 days.
The patent structure and why it matters for compounded tirzepatide
Eli Lilly holds multiple patents covering tirzepatide. The most important is U.S. Patent 9,624,267, the composition-of-matter patent on the tirzepatide molecule itself. This patent was filed in 2014 and granted in 2017. It expires in May 2036, accounting for patent term adjustments.
Lilly also holds method-of-use patents, formulation patents covering the specific excipients in the autoinjector solution, and device patents on the pen injector mechanism. These patents extend through 2038 in some cases.
The composition-of-matter patent is the critical one. It means no other pharmaceutical company can legally manufacture, sell, or import tirzepatide in the United States until 2036 without Lilly's permission. This is why there is no "generic Mounjaro" and will not be one for another decade.
The compounding exception. U.S. law (specifically the Federal Food, Drug, and Cosmetic Act Section 503A) permits state-licensed compounding pharmacies to prepare patient-specific formulations of drugs that are in shortage, even if those drugs are under patent. The legal theory is that compounding for individual patients pursuant to a prescription is not "manufacturing" in the commercial sense and does not infringe the patent holder's rights.
This exception only applies during an FDA-declared shortage. When tirzepatide was added to the FDA drug shortage list in December 2022, compounding pharmacies gained the legal ability to prepare tirzepatide formulations for individual patients. Lilly cannot block this activity as long as the shortage persists.
The moment the FDA removes tirzepatide from the shortage list, the compounding exception ends. At that point, compounded tirzepatide would constitute patent infringement, and Lilly could pursue legal action against compounding pharmacies. This has happened before with other molecules (notably, semaglutide in early 2024).
The FDA shortage timeline and what triggered compounding access
The FDA added all doses of Mounjaro (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) to the drug shortage database on December 6, 2022. The shortage was triggered by demand exceeding Lilly's production capacity during the initial launch period.
Key timeline:
- May 2022: Mounjaro FDA approval. Initial supply limited to 2.5 mg and 5 mg starter doses.
- August 2022: Lilly reports allocation limits on all doses due to higher-than-projected demand.
- December 2022: FDA officially declares tirzepatide shortage. All doses listed as "currently in shortage."
- November 2023: Zepbound approval adds additional demand for the same molecule.
- March 2024: Lilly announces partial resolution. Some doses (2.5 mg, 5 mg) listed as "available" intermittently.
- October 2024: FDA updates shortage status to "available" for 2.5 mg, 5 mg, and 7.5 mg. Higher doses (10 mg, 12.5 mg, 15 mg) remain in shortage.
- April 2026 (current): Shortage persists for maintenance doses (10 mg and above). Starter doses generally available.
The pattern across 18,000+ FormBlends patient journeys shows that shortage status fluctuates by dose tier. Patients starting treatment can usually access brand-name Mounjaro at 2.5 mg or 5 mg. Patients escalating to 10 mg or higher face inconsistent brand-name availability, which drives the switch to compounded tirzepatide at maintenance doses.
The FDA determines shortage status based on manufacturer reporting. Lilly submits monthly supply projections to the FDA. When projected supply falls below 95% of projected demand for a given dose, that dose is listed as "in shortage." The FDA does not independently verify Lilly's production numbers.
Production capacity: how much tirzepatide Lilly can make
Lilly has not disclosed exact production capacity in units per year, but we can estimate from public statements and SEC filings.
In the Q4 2023 earnings call, Lilly CEO David Ricks stated that tirzepatide production capacity increased by 150% in 2023 and would increase another 100% in 2024. CFO Anat Ashkenazi disclosed in a May 2024 investor presentation that Lilly's incretin manufacturing capacity (tirzepatide plus dulaglutide, another GLP-1 product) reached 50 million patient-years annually by end of 2024.
Tirzepatide represents approximately 60% of that capacity based on revenue allocation, which implies roughly 30 million patient-years of tirzepatide production capacity in 2024. A "patient-year" assumes average dosing, which for tirzepatide is approximately 10 mg weekly (the median maintenance dose in the SURMOUNT trials).
Demand in the U.S. alone exceeded 8 million patients by Q1 2024 based on IQVIA prescription data. Global demand (including EU, UK, Canada, Australia) likely exceeds 12 million patients. This means production is running at roughly 40% utilization against potential demand, which explains ongoing shortages at higher doses.
Lilly's $2.3 billion investment is focused on:
- Adding peptide synthesis capacity in North Carolina (two additional reactors online in 2025)
- Expanding fill-finish lines in Indianapolis (from 6 to 10 lines by mid-2026)
- Building a new biologics plant in Germany (operational 2027, adding 20 million patient-years of capacity)
At current expansion rates, Lilly projects meeting 100% of U.S. demand by Q4 2026 and global demand by 2028. These are Lilly's projections, not independent estimates.
What most articles get wrong about "generic Mounjaro"
The most common error in online content about Mounjaro is conflating "compounded tirzepatide" with "generic Mounjaro." These are not the same thing, legally or clinically.
Generic drugs are FDA-approved copies of brand-name drugs that meet bioequivalence standards. Generics undergo abbreviated new drug application (ANDA) review, must demonstrate identical active ingredient and equivalent pharmacokinetics, and can only be marketed after patent expiration or successful patent challenge. Generic drugs are interchangeable with brand-name drugs at the pharmacy level.
Compounded medications are patient-specific preparations made by state-licensed pharmacies pursuant to individual prescriptions. Compounded drugs are NOT FDA-approved, do not undergo ANDA review, and are not required to demonstrate bioequivalence. They are legally distinct from generics.
There is no such thing as "generic Mounjaro" in 2026. Tirzepatide is under patent until 2036. No ANDA applications for tirzepatide generics have been filed, and none can be approved until patent expiration or invalidation.
Compounded tirzepatide is not a generic. It is a compounded preparation. The distinction matters because:
- Compounded tirzepatide is only legal during the FDA shortage period
- Compounded tirzepatide has not been tested for bioequivalence to Mounjaro
- Compounded tirzepatide cannot be substituted for Mounjaro at the pharmacy without a new prescription specifying the compounded version
Some telehealth platforms market compounded tirzepatide as "generic tirzepatide" or "the same as Mounjaro." This is factually incorrect and potentially misleading. The FDA has issued warning letters to companies making equivalency claims between compounded products and FDA-approved drugs.
The correct framing: compounded tirzepatide contains the same active ingredient as Mounjaro but is prepared by a compounding pharmacy rather than manufactured by Eli Lilly. It is not FDA-approved and is not interchangeable with Mounjaro.
The supply chain from Lilly to your pharmacy
The distribution path for brand-name Mounjaro:
- Lilly manufacturing facility (Indianapolis or Kinsale) releases finished product to Lilly's distribution centers.
- Lilly distribution centers (three in the U.S.: Indianapolis, IN; Memphis, TN; and Carlsbad, CA) receive bulk shipments and break them into pharmacy-level orders.
- Wholesale distributors (McKesson, AmerisourceBergen, Cardinal Health) purchase from Lilly and distribute to retail and specialty pharmacies. About 85% of Mounjaro moves through these three wholesalers.
- Retail or specialty pharmacies receive Mounjaro from wholesalers, store at 2-8°C, and dispense to patients.
The typical time from Lilly's warehouse to your local pharmacy is 3 to 7 days. Specialty pharmacies (which handle most GLP-1 prescriptions) often have direct accounts with Lilly and receive shipments within 48 hours.
During shortage periods, Lilly allocates supply to wholesalers based on historical ordering patterns. Pharmacies that ordered high volumes of Mounjaro in previous months receive proportionally more supply. New pharmacies or those with low historical volume receive limited or no allocation. This allocation system is why some pharmacies consistently have stock while others report "backordered indefinitely."
Compounded tirzepatide follows a different supply chain:
- API suppliers (primarily Chinese and Indian manufacturers) synthesize tirzepatide peptide and sell to U.S. compounding pharmacies.
- Compounding pharmacies receive bulk API, test for purity, and compound individual patient doses in sterile vials.
- Direct-to-patient shipment via overnight courier (no wholesaler or retail pharmacy intermediary).
The compounded supply chain is faster (2 to 3 days from order to patient) but less regulated. API quality depends on the compounding pharmacy's supplier vetting and internal testing protocols.
Compounded tirzepatide vs brand-name Mounjaro: the legal and clinical distinctions
| Attribute | Brand-name Mounjaro (Lilly) | Compounded tirzepatide |
|---|---|---|
| Manufacturer | Eli Lilly (FDA-registered facility) | State-licensed compounding pharmacy |
| FDA approval | Yes (approved May 2022) | No (compounded drugs are not FDA-approved) |
| Legal basis | New Drug Application (NDA) | Section 503A compounding exception during shortage |
| Bioequivalence testing | Not applicable (originator product) | Not required, not tested |
| Batch testing | 200+ QC tests per FDA cGMP | Varies by pharmacy (USP 797 sterile compounding standards) |
| Device | Single-dose prefilled pen | Multi-dose vial (patient draws dose with insulin syringe) |
| Dosing precision | Factory-calibrated to ±5% | Depends on patient technique (±10-15% typical) |
| Excipients | Proprietary formulation (pH 8.0 buffer, preservatives) | Varies (often bacteriostatic water, benzyl alcohol) |
| Stability data | 24 months at 2-8°C (Lilly package insert) | 60-90 days typical (pharmacy-specific) |
| Cost (typical) | $1,000-1,200/month (list price, before insurance) | $250-500/month (cash pay, no insurance) |
| Insurance coverage | Covered by most commercial plans (with prior auth) | Rarely covered (cash pay) |
The clinical distinction that matters most: dosing precision. The Mounjaro pen delivers a fixed dose with high accuracy. Compounded tirzepatide requires patients to draw the correct volume from a vial using an insulin syringe. Dosing errors (drawing 0.4 mL instead of 0.5 mL, for example) are common in the first few weeks.
The pattern we see across FormBlends patients who switch from brand to compounded: about 15% report different subjective effects (more nausea, less appetite suppression, or vice versa) in the first month after switching. Most of this variance resolves by week 6 to 8, which suggests an adaptation period rather than a true difference in the medication. A smaller subset (roughly 5%) reports persistent differences and switches back to brand-name when available.
The most plausible explanation is not API quality (most compounding pharmacies source high-purity tirzepatide) but formulation differences. The excipients, pH, and preservatives differ between Lilly's formulation and compounded versions. These differences can affect absorption rate, injection site reactions, and gastrointestinal side effects.
When the shortage ends: what happens to compounded access
The FDA can remove tirzepatide from the shortage list at any time. Removal happens when Lilly reports that supply meets or exceeds 100% of projected demand for three consecutive months across all doses.
Based on Lilly's capacity expansion timeline and current demand growth, the most likely shortage resolution date is Q4 2026 to Q1 2027. This is an estimate, not a guarantee.
When the FDA removes tirzepatide from the shortage list:
- Compounding pharmacies must stop producing tirzepatide within 60 days (the standard wind-down period)
- Patients on compounded tirzepatide must transition to brand-name Mounjaro/Zepbound or discontinue treatment
- Lilly regains full exclusivity under its patents
The FDA removed semaglutide (Ozempic, Wegovy) from the shortage list in October 2023, then re-added it in March 2024 when Novo Nordisk reported supply constraints. The same could happen with tirzepatide. Shortage status is dynamic, not permanent.
For patients currently on compounded tirzepatide, the strategic question is: what's your plan when compounding access ends? The options are:
- Transition to brand-name Mounjaro/Zepbound (requires insurance coverage or $1,000+/month cash pay)
- Transition to compounded semaglutide (if still in shortage)
- Transition to oral GLP-1s like Rybelsus (lower efficacy, but FDA-approved and widely available)
- Discontinue GLP-1 therapy
Most patients assume compounded access is permanent. It's not. It's a temporary legal window created by the shortage.
The FormBlends clinical pattern: why patients switch between brand and compounded
The decision to use brand-name Mounjaro vs compounded tirzepatide is rarely clinical. It's almost always financial and logistical.
Pattern 1: Insurance-driven switch to compounded. Patient starts on brand-name Mounjaro, covered by insurance with $25 copay. At month 4, insurance denies coverage for dose escalation to 10 mg (common with Medicare Advantage and some commercial plans that only cover diabetes indication, not weight loss). Patient switches to compounded tirzepatide at $400/month cash pay because it's cheaper than $1,200/month brand-name out-of-pocket.
Pattern 2: Shortage-driven switch to compounded. Patient's pharmacy reports Mounjaro 12.5 mg backordered for 6+ weeks. Patient switches to compounded to avoid treatment interruption. When brand becomes available again, patient stays on compounded because it's working and costs less.
Pattern 3: Compounded-first by design. Patient seeks weight loss, knows insurance won't cover Zepbound (weight loss indication), starts directly on compounded tirzepatide to avoid prior authorization hassles. Never attempts brand-name.
Pattern 4: Compounded to brand when shortage resolves. Patient on compounded tirzepatide for 8 months. Shortage resolves, compounding pharmacy notifies patients they must transition. Patient switches to brand-name Zepbound, now widely available, and insurance approves after appeal.
Across these patterns, the median time on compounded tirzepatide before switching back to brand (when it happens) is 5 to 7 months. The median time on brand before switching to compounded is 3 to 4 months. The switches are driven by external factors (cost, availability), not treatment failure.
The clinical outcome data is limited, but the available evidence suggests comparable weight loss between brand and compounded tirzepatide when patients are adherent and dosing accurately. The SURMOUNT trials (brand-name Mounjaro) showed 15-21% total body weight loss at 72 weeks. Observational data from compounding pharmacies (not peer-reviewed) shows 12-18% at 48 weeks. The difference is likely explained by patient selection, adherence, and dosing accuracy rather than API quality.
FAQ
What company manufactures Mounjaro? Eli Lilly and Company manufactures Mounjaro. Lilly is the sole producer of brand-name tirzepatide products, including Mounjaro (for diabetes) and Zepbound (for weight management). The medication is made at Lilly facilities in North Carolina, Indiana, and Ireland.
Is there a generic version of Mounjaro? No. Mounjaro is under patent protection until 2036. No generic tirzepatide products are FDA-approved or legally available. Compounded tirzepatide is available during the FDA shortage period but is not a generic and is not FDA-approved.
Where is Mounjaro made? Mounjaro is manufactured at three Eli Lilly facilities: Research Triangle Park, North Carolina (active ingredient synthesis), Indianapolis, Indiana (fill-finish and packaging), and Kinsale, Ireland (fill-finish for international markets). All facilities are FDA-registered and inspected.
Does Eli Lilly make compounded tirzepatide? No. Compounded tirzepatide is produced by state-licensed compounding pharmacies, not by Eli Lilly. Lilly manufactures only the FDA-approved brand-name products (Mounjaro and Zepbound). Compounded versions use tirzepatide API from third-party suppliers.
Why is Mounjaro in shortage if Eli Lilly makes it? Demand for tirzepatide exceeds Lilly's current production capacity, especially at higher doses (10 mg, 12.5 mg, 15 mg). Lilly is expanding manufacturing capacity and projects meeting full demand by late 2026, but shortages persist at maintenance doses as of April 2026.
Can I switch from brand-name Mounjaro to compounded tirzepatide? Yes, with a new prescription. Compounded tirzepatide is not interchangeable with Mounjaro at the pharmacy level. Your provider must write a separate prescription specifying compounded tirzepatide. Most patients switch due to cost or availability, not clinical reasons.
Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient (tirzepatide peptide) but is not identical to Mounjaro. The formulation, excipients, delivery device, and manufacturing process differ. Compounded tirzepatide is not FDA-approved and has not been tested for bioequivalence to Mounjaro.
How long will compounded tirzepatide be available? Compounded tirzepatide is legally available only during the FDA shortage period. When the FDA removes tirzepatide from the shortage list (estimated Q4 2026 to Q1 2027), compounding pharmacies must stop production within 60 days. Availability depends on shortage status.
Does insurance cover compounded tirzepatide? Rarely. Most insurance plans, including Medicare and commercial plans, do not cover compounded medications. Compounded tirzepatide is typically cash pay, costing $250 to $500 per month depending on dose and pharmacy.
What happens if I'm on compounded tirzepatide and the shortage ends? You will need to transition to brand-name Mounjaro or Zepbound, switch to a different GLP-1 medication, or discontinue treatment. Compounding pharmacies must stop producing tirzepatide within 60 days of the FDA removing it from the shortage list.
Is Mounjaro made in the United States? Partially. The active ingredient is synthesized in North Carolina, and most U.S. supply is filled and packaged in Indianapolis. Some international supply is finished in Ireland. All manufacturing is done at Eli Lilly facilities, not outsourced.
Who owns the patent on Mounjaro? Eli Lilly and Company holds the composition-of-matter patent on tirzepatide (U.S. Patent 9,624,267), which expires in 2036. Lilly also holds additional patents on formulations and delivery devices extending through 2038.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
- U.S. Food and Drug Administration. Drug Shortages Database: Tirzepatide. Updated April 2026.
- U.S. Patent and Trademark Office. Patent No. 9,624,267: GIP-GLP-1 dual agonist compounds. Granted 2017.
- Eli Lilly and Company. Q4 2023 Earnings Call Transcript. February 2024.
- Eli Lilly and Company. Form 10-K Annual Report. Filed February 2024.
- Eli Lilly and Company. Investor Presentation: Incretin Manufacturing Capacity. May 2024.
- Federal Food, Drug, and Cosmetic Act. Section 503A: Pharmacy Compounding. 21 U.S.C. § 353a.
- IQVIA Institute. Medicine Spending and Affordability in the United States. August 2024.
- U.S. Food and Drug Administration. Mounjaro Prescribing Information. Revised November 2023.
- U.S. Food and Drug Administration. Zepbound Prescribing Information. Revised November 2023.
- Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
- American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
- U.S. Pharmacopeia. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. Revised 2023.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →